60.62

1.32% 0.79

Pre-market: 60.66 0.04 +0.07%

Travere Therapeutics Inc (TVTX)

Overview News Price History Option Chain Financials Why TVTX Down? Discussions Forecast Stock Split

Travere Therapeutics Inc stock is traded at $60.62, with a volume of 1.76M. It is up +1.32% in the last 24 hours and down -7.05% over the past month. Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

Previous Close:

$59.83

Open:

$60

24h Volume:

1.76M

Relative Volume:

1.10

Market Cap:

$5.71B

Revenue:

$536.20M

Net Income/Loss:

$-45.64M

P/E Ratio:

-113.35

EPS:

-0.5348

Net Cash Flow:

$-28.94M

1W Performance:

-6.36%

1M Performance:

-7.05%

6M Performance:

+126.28%

1Y Performance:

+148.34%

1-Day Range:

$59.22

$60.80

1-Week Range:

$58.32

$64.89

52-Week Range:

$22.05

$68.73

Travere Therapeutics Inc Stock (TVTX) Company Profile

Name

Travere Therapeutics Inc

Sector

Healthcare (1068)

Industry

Biotechnology (595)

Phone

888-969-7879

Address

3611 VALLEY CENTRE DR, SAN DIEGO

Employee

497

Twitter

Next Earnings Date

2026-10-29

Latest SEC Filings

TVTX's Discussions on Twitter

Compare TVTX vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TVTX Travere Therapeutics Inc	60.62	5.71B	536.20M	-45.64M	-28.94M	-0.5348
VRTX Vertex Pharmaceuticals Inc	522.38	132.40B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	796.02	81.95B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	194.82	77.78B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	962.22	60.20B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	199.86	42.84B	742.00K	-1.37B	-1.07B	-7.0731

Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-14-26	Upgrade	Piper Sandler	Neutral → Overweight
Oct-31-25	Reiterated	Citigroup	Buy
Jun-11-25	Reiterated	Citigroup	Buy
Jun-11-25	Resumed	H.C. Wainwright	Buy
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Oct-21-24	Upgrade	Wells Fargo	Equal Weight → Overweight
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Sep-09-24	Upgrade	Guggenheim	Neutral → Buy
Mar-27-24	Downgrade	Guggenheim	Buy → Neutral
Dec-05-23	Upgrade	Citigroup	Neutral → Buy
Nov-20-23	Initiated	Citigroup	Neutral
Sep-22-23	Downgrade	Wells Fargo	Overweight → Equal Weight
Sep-21-23	Downgrade	William Blair	Outperform → Mkt Perform
Sep-06-23	Resumed	Evercore ISI	Outperform
Jul-21-23	Initiated	JP Morgan	Overweight
Jun-07-23	Resumed	Piper Sandler	Neutral
May-22-23	Initiated	TD Cowen	Outperform
May-05-23	Upgrade	Bryan Garnier	Sell → Neutral
Mar-01-23	Initiated	Guggenheim	Buy
Feb-21-23	Upgrade	Wedbush	Neutral → Outperform
Dec-14-22	Initiated	Stifel	Hold
Dec-05-22	Initiated	Wells Fargo	Overweight
Sep-21-22	Initiated	Bryan Garnier	Sell
Jul-14-22	Resumed	Canaccord Genuity	Buy
Mar-31-22	Initiated	Piper Sandler	Overweight
Feb-28-22	Initiated	H.C. Wainwright	Buy
May-26-21	Downgrade	Wedbush	Outperform → Neutral

View All

Travere Therapeutics Inc Stock (TVTX) Latest News

Sep 24, 2026

TVTX Maintained by Guggenheim -- Price Target Raised to $89.00 - GuruFocus

Sep 24, 2026

Guggenheim raises Travere Therapeutics stock price target on patent By Investing.com - Investing.com Canada

Sep 24, 2026

Sep 23, 2026

Understanding the Setup: (TVTX) and Scalable Risk - news.stocktradersdaily.com

Sep 23, 2026

Travere Therapeutics Receives US Patent Allowance for Kidney Disease Drug FILSPARI - marketscreener.com

Sep 23, 2026

Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in Focal Segmental Glomerulosclerosis - BioSpace

Sep 23, 2026

Travere receives patent allowance for FILSPARI use in FSGS - Investing.com

Sep 23, 2026

Travere TherapeuticsReceives USPTO Notice Of Allowance For Filspari Patent In FSGS - TradingView

Sep 23, 2026

Sep 22, 2026

TVTX Stock Slides 6% On Everest Deal, Erases Some Losses As Analyst Sees 49% Upside - Stocktwits

Sep 22, 2026